drugset / Trial / NCT02756546

Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

NCT02756546

Phase 1/2 Completed 100 enrolled Cairo University
RandomizedParallel-groupOpen-labelDiagnostic

Summary

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Timeline

Start
2014-09
Primary completion
2015-09
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified
Comparator Hydrocortisone Other / unclassified
Comparator Hydroxychloroquine Small molecule